CROSSJECT (EPA:ALCJ)

PRESS RELEASE

published on 06/24/2025 at 19:00, 1 year ago

CROSSJECT announces a successful capital increase of €5.7 million following full exercise of the extension clause
CROSSJECT successfully completes a capital increase of €5.7 million through preferential subscription rights, benefiting from new investor support and Gemmes Venture, to advance ZEPIZURE® development

Capital Increase Crossject ZEPIZURE® Gemmes Venture Vatel Capital
BRIEF

published on 06/11/2025 at 07:35, 1 year 1 month ago

CROSSJECT advances in the development of ZEPIZURE® Junior for children

Epilepsy Pediatrics Crossject Auto-injector ZEPIZURE Junior
PRESS RELEASE

published on 06/11/2025 at 07:30, 1 year 1 month ago

CROSSJECT advances on the development of ZEPIZURE® Junior, its solution for epilepsy crises in children
CROSSJECT advances development of ZEPIZURE® Junior for epilepsy crises in children, completing clinical studies for effective calibration and injection depth validation

Epilepsy Clinical Studies Crossject ZEPIZURE® Junior Pediatric Population
BRIEF

published on 06/06/2025 at 17:50, 1 year 1 month ago

Publication of Crossject voting rights and shares

Share Capital Voting Rights Actions AMF Crossject
BRIEF

published on 06/04/2025 at 20:26, 1 year 1 month ago

CROSSJECT launches a capital increase of nearly 5 million euros

Investment Pharmaceutical Capital Increase Preferential Subscription Right ZEPIZURE®
PRESS RELEASE

published on 06/04/2025 at 20:21, 1 year 1 month ago

Launch of a capital increase with preferential subscription rights for nearly 5 million euros
CROSSJECT announces capital increase with preferential subscription rights totaling nearly 5 million euros. Existing shareholders and Vatel Capital commit to subscribe 76.4% of the amount. Subscription price set at 1.40 euros. Subscription period from June 12 to June 20, 2025

Capital Increase Subscription Period Preferential Subscription Rights Crossject Vatel Capital
BRIEF

published on 06/03/2025 at 07:35, 1 year 1 month ago

Maxim Group Recommends CROSSJECT with €4.00 Target Price

Buy Recommendation Crossject ZEPIZURE® Needle-free Auto-injector Maxim Group
PRESS RELEASE

published on 06/03/2025 at 07:30, 1 year 1 month ago

Maxim Group initiates the coverage of the CROSSJECT share with a BUY recommendation and a target price of €4.00
Maxim Group initiates coverage of CROSSJECT with BUY recommendation and €4.00 target price. CROSSJECT, a specialty pharma company, looks forward to positive developments with FDA and pipeline

FDA Buy Recommendation Specialty Pharma Crossject Maxim Group
BRIEF

published on 05/27/2025 at 07:35, 1 year 1 month ago

CROSSJECT optimizes its production with the ZENEO® Nest

CDMO Funding Production Crossject ZENEO® Nest
BRIEF

published on 05/20/2025 at 07:35, 1 year 2 months ago

CROSSJECT Plans €5 Million Capital Increase to Boost EUA Approval Activities

Capital Increase Crossject ZEPIZURE® Gemmes Venture EUA Approval

Published on 07/21/2026 at 17:05, 4 hours 33 minutes ago

Caldwell Appoints Steven Price Co-Leader of Life Sciences & Healthcare Practice
Published on 07/21/2026 at 15:00, 6 hours 38 minutes ago

Four Nines Gold Begins Maiden Drill Program at Hayden Hill
Published on 07/21/2026 at 15:00, 6 hours 38 minutes ago

BlackBerry SecuSUITE Secures Renewed NIAP Common Criteria Certification, Reinforcing Leadership in Sovereign Government-Grade Secure Communications
Published on 07/21/2026 at 14:55, 6 hours 43 minutes ago

Vulcan Minerals Inc. - Drilling Completed at Carbonear Zinc-Lead SEDEX Project in Newfoundland
Published on 07/21/2026 at 14:30, 7 hours 8 minutes ago

Sarama Completes Sale of its West Australian Gold Assets

View all ACCESSWIRE

Published on 07/21/2026 at 18:50, 2 hours 48 minutes ago

Soapeya, a DN Group AG Portfolio Company, Earns Top "Excellent" Rating from Dermatest and Proves Successful in Field Use in Ghana
Published on 07/21/2026 at 18:15, 3 hours 23 minutes ago

EuroTeleSites Reports Strong Q2/2026 Results with Growth Across Key Financial and Operating Metrics
Published on 07/21/2026 at 17:50, 3 hours 48 minutes ago

The New Measure of an EV Isn't Range, It's Peace of Mind
Published on 07/21/2026 at 17:40, 3 hours 58 minutes ago

EQS-Adhoc: Airbus to present new mid-term outlook, strengthen commitment to profitable growth and shareholder returns during investor update
Published on 07/21/2026 at 17:37, 4 hours 1 minute ago

EQS-Adhoc: Branicks Group AG updates the timetable for the publication of its 2025 annual and consolidated financial statements in light of ongoing restructuring negotiations

View all EQS

Published on 07/21/2026 at 18:41, 2 hours 57 minutes ago

ICADE - 2026 HY Financial Report
Published on 07/21/2026 at 18:13, 3 hours 25 minutes ago

ICADE – PR – 2026 HALF YEAR RESULTS
Published on 07/20/2026 at 18:20, 1 day 3 hours ago

Covivio - 2026 Half-year results: Earnings growth driven by active asset management
Published on 07/20/2026 at 18:04, 1 day 3 hours ago

Reporting on share buyback transactions carried out between July 8 and July 9, 2026
Published on 07/20/2026 at 17:45, 1 day 3 hours ago

Weekly share buyback

View all LES ECHOS COMFI WIRE

News